Using real-world data for coverage and payment decisions: the ISPOR Real-World Data Task Force report.
about
Considerations for observational research using large data sets in radiation oncologyReal world evidence: An Indian perspectiveAssessing the outcomes of implantable cardioverter defibrillator treatment in a real world setting: results from hospital record dataStandards should be applied in the prevention and handling of missing data for patient-centered outcomes research: a systematic review and expert consensus.Can administrative data be used to measure chemotherapy side effects?Real world data: Additional source for making clinical decisions.Hypoglycemia Event Rates: A Comparison Between Real-World Data and Randomized Controlled Trial Populations in Insulin-Treated Diabetes.USING CLAIMS DATA FOR EVIDENCE GENERATION IN MANAGED ENTRY AGREEMENTS.Real-world data in the United Kingdom: opportunities and challengesBig Data: transforming drug development and health policy decision makingDemographics of patients receiving Intravitreal anti-VEGF treatment in real-world practice: healthcare research data versus randomized controlled trials.Greater first year effectiveness drives favorable cost-effectiveness of brand risedronate versus generic or brand alendronate: modeled Canadian analysis.Integrating patients into meaningful real-world research.Effectiveness of triple therapy with direct-acting antivirals for hepatitis C genotype 1 infection: application of propensity score matching in a national HCV treatment registry.Principles of pharmacoeconomics and their impact on strategic imperatives of pharmaceutical research and developmentObservational studies: a valuable source for data on the true value of RA therapies.Effectiveness of anti-tumor necrosis factor agents in the treatment of rheumatoid arthritis: observational studyMechanisms of action of bisphosphonates: similarities and differences and their potential influence on clinical efficacy.A systematic review of economic evaluations of interventions to tackle cardiovascular disease in low- and middle-income countriesTemporal variability of antibiotics fluxes in wastewater and contribution from hospitals.The clinical decision analysis using decision treePharmacoeconomic studies in Nepal: the need of the hour.Do economic evaluations of targeted therapy provide support for decision makers?Risk of osteonecrosis in patients taking bisphosphonates for prevention of osteoporosis: a systematic review and meta-analysis.Protocol for the economic evaluation of the diarrhea alleviation through zinc and oral rehydration salt therapy at scale through private and public providers in rural Gujarat and Uttar Pradesh, IndiaEverolimus-Based Therapy versus Chemotherapy among Patients with HR+/HER2- Metastatic Breast Cancer: Comparative Effectiveness from a Chart Review Study.Healthcare Databases in Thailand and Japan: Potential Sources for Health Technology Assessment Research.Real-world cost analysis of chemotherapy for colorectal cancer in Japan: detailed costs of various regimens during the entire course of chemotherapyPatient Characteristics, Safety, and Tolerability with Telaprevir Treatment for HCV in the Clinic: a Retrospective, Multicenter Study.Is real world evidence influencing practice? A systematic review of CPRD research in NICE guidances.Real World Data in Adaptive Biomedical Innovation: A Framework for Generating Evidence Fit for Decision-Making.Cost analysis of glatiramer acetate versus interferon-β for relapsing-remitting multiple sclerosis in patients with spasticity: the Escala studySystematic Review and Meta-Analysis of Tacrolimus versus Ciclosporin as Primary Immunosuppression After Liver TransplantPhysician experiences and preferences in the treatment of HR+/HER2- metastatic breast cancer in the United States: a physician surveyCost-effectiveness analysis of fesoterodine flexible dose in newly diagnosed patients with overactive bladder in routine clinical practice in Spain.Potential role of exosome-associated microRNA panels and in vivo environment to predict drug resistance for patients with multiple myeloma.Randomized controlled trials and real-world observational studies in evaluating cardiovascular safety of inhaled bronchodilator therapy in COPD.Economic evaluation of capecitabine as adjuvant or metastatic therapy in colorectal cancer.Real-world resource use and costs of adjuvant treatment for stage III colon cancer.Current situation and challenge of registry in China.
P2860
Q24289442-E89660C8-0ABD-436C-909D-0C8397B15C10Q28074506-1381D0C9-F6F6-4014-9725-1748CB941284Q30599499-B1D7D545-505E-4146-B5E5-017FB2E60BC3Q30699551-23D1AAD2-A4DA-4112-81AA-C02831424E93Q30877306-416FD77C-0B4F-4FC2-95C0-71C0C67CE005Q30975806-2531DAA9-7E42-427F-B80F-926325DF75D0Q31046934-30C0BC07-3916-4B29-B96E-13A07C98D470Q31058117-F3E86D54-296B-4946-A4C7-2ECE224B4536Q31110524-5DDE9E6D-5F14-4B05-825A-97C1C2170A50Q31126744-0B181888-9A44-4E04-9E0D-18D3B2D74475Q31155420-98E487B3-96CA-4CF9-8ECC-B72D6E1BF3FBQ33305959-035E8B08-2AC8-4C14-B63E-B05B175AA67EQ33440620-E4D5CAC5-C5FF-4493-A3E2-4B3F53429E52Q33576871-96603AEC-B216-4F90-84E6-CFC104E4D21BQ33772852-5990F501-2BA8-4D5A-97B6-C7521DB26594Q33779130-B89169EA-B5BE-4623-9A76-91D811FAF750Q33932391-7B29896C-3C4C-42C0-A1AA-FBC927F0A4CAQ34009569-49698990-C4D7-498A-A5EE-DF1B53F0AE2DQ34116368-044A4EDD-9B29-4F2B-A15A-D1E7D7D0A97EQ34548303-1B05BC1D-6A03-45A6-8826-1C30E86C7665Q34608270-1A2AFB35-6311-44B9-ABD7-AE5594DEE161Q34650925-0F147E9F-6FF6-47D7-AF9A-7E92B7745824Q34974213-A778F8C8-AD8D-40ED-A7C7-8C6C1755E801Q35068631-F9C27726-045C-4803-893E-90E1039B133FQ35104420-E4FFFB27-123B-4747-90D1-8A165B3B0616Q35675851-0074908E-7D21-4012-8FE3-D3AA48410CC7Q35839046-F418E41E-0A72-4B39-B152-F3B0F331EAECQ35884411-37689152-105C-4AF7-B4CF-F4E2049F21FEQ35905994-490EF942-4EE5-400B-B261-F485971C64E5Q36085309-C0B27EF7-60B6-4D10-B1A7-9CF5EF7A4B84Q36132510-00D57236-E823-4D22-9443-AD846FF423C4Q36171531-5AE78AA9-B752-428C-96CD-8203CC898409Q36182011-3AEC2981-DD35-427B-85E6-2398D9E40A54Q36528355-02EAA1C4-CC25-4F53-B4B5-8FE08DC48227Q37300812-8E18F1C0-FD01-4DAE-914C-AD289853BA7CQ37327618-6B94484D-7205-4576-9268-5CA515E2431AQ37468663-218B3639-F3A7-443B-BAFA-7DB92F8B2C91Q37729193-EA4E20AC-3221-45F6-A83D-69092385CC15Q38174218-9E480659-B786-40FC-99E6-4FA4AE0E47E3Q38245893-8274BAF2-6A47-4E84-B5F3-9F5928465A07
P2860
Using real-world data for coverage and payment decisions: the ISPOR Real-World Data Task Force report.
description
2007 nî lūn-bûn
@nan
2007 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2007 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2007年の論文
@ja
2007年学术文章
@wuu
2007年学术文章
@zh-cn
2007年学术文章
@zh-hans
2007年学术文章
@zh-my
2007年学术文章
@zh-sg
2007年學術文章
@yue
name
Using real-world data for cove ...... -World Data Task Force report.
@ast
Using real-world data for cove ...... -World Data Task Force report.
@en
type
label
Using real-world data for cove ...... -World Data Task Force report.
@ast
Using real-world data for cove ...... -World Data Task Force report.
@en
prefLabel
Using real-world data for cove ...... -World Data Task Force report.
@ast
Using real-world data for cove ...... -World Data Task Force report.
@en
P2093
P1433
P1476
Using real-world data for cove ...... l-World Data Task Force report
@en
P2093
Louis P Garrison
Pennifer Erickson
Peter J Neumann
P304
P356
10.1111/J.1524-4733.2007.00186.X
P577
2007-09-01T00:00:00Z